Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection.

[1]  L. Grohskopf,et al.  Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2018–19 Influenza Season , 2015, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[2]  M. Fisberg,et al.  Obesogenic environment - intervention opportunities. , 2016, Jornal de pediatria.

[3]  M. Drummond,et al.  Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial. , 2015, The Lancet. Infectious diseases.

[4]  C. Robertson,et al.  Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty. , 2015, Vaccine.

[5]  D. Linkin,et al.  Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  C. Fonnesbeck,et al.  Randomized, double‐blind comparison of standard‐dose vs. high‐dose trivalent inactivated influenza vaccine in pediatric solid organ transplant patients , 2015, Pediatric transplantation.

[7]  Thomas MaCurdy,et al.  Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. , 2015, The Lancet. Infectious diseases.

[8]  S. Riley,et al.  Longevity and determinants of protective humoral immunity after pandemic influenza infection. , 2015, American journal of respiratory and critical care medicine.

[9]  John Earl,et al.  Efficacy of high-dose versus standard-dose influenza vaccine in older adults. , 2014, The New England journal of medicine.

[10]  C. Diazgranados,et al.  Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial. , 2014, Vaccine.

[11]  C. Robertson,et al.  Prevention of Serious Events in Adults 65 Years of Age or Older: A Comparison Between High-dose and Standard-dose Inactivated Influenza Vaccines , 2014 .

[12]  J. McCullers,et al.  Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia , 2013, Pediatric blood & cancer.

[13]  L. Kremer,et al.  Influenza vaccination in children being treated with chemotherapy for cancer. , 2013, The Cochrane database of systematic reviews.

[14]  C. Diazgranados,et al.  High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. , 2013, Vaccine.

[15]  I. Frank,et al.  Improved Immunogenicity With High-Dose Seasonal Influenza Vaccine in HIV-Infected Persons , 2013, Annals of Internal Medicine.

[16]  J. McCullers,et al.  Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults. , 2012, Vaccine.

[17]  S. Madhi,et al.  Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  A. Jawad,et al.  The Efficacy of Influenza Vaccination in a Pediatric Oncology Population , 2010, Journal of pediatric hematology/oncology.

[19]  R. Webby,et al.  Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  P. Salamati,et al.  Immunogenicity of trivalent influenza vaccine in children with acute lymphoblastic leukemia during maintenance therapy , 2010, Pediatric blood & cancer.

[21]  E. Janoff,et al.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. , 2009, The Lancet. Infectious diseases.

[22]  A. Falsey,et al.  Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. , 2009, The Journal of infectious diseases.

[23]  M. Jonges,et al.  Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. , 2009, The Journal of infectious diseases.

[24]  N. Khardori.  Prolonged Influenza Virus Infection during Lymphocytopenia and Frequent Detection of Drug-Resistant Viruses , 2009 .

[25]  L. Kremer,et al.  Influenza vaccination in children being treated with chemotherapy for cancer. , 2009, The Cochrane database of systematic reviews.

[26]  J. Englund,et al.  Influenza‐associated morbidity in children with cancer , 2008, Pediatric blood & cancer.

[27]  A. Oğuz,et al.  Assessment of the immune response to trivalent split influenza vaccine in children with solid tumors , 2007, Pediatric blood & cancer.

[28]  R. Couch,et al.  Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. , 2007, Vaccine.

[29]  R. Couch,et al.  Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. , 2006, Archives of internal medicine.

[30]  A. Suminoe,et al.  Immune response after influenza vaccination in children with cancer , 2005, Pediatric blood & cancer.

[31]  M. Zambon,et al.  Influenza immunisation in children with solid tumours. , 2005, European journal of cancer.

[32]  K. Edwards,et al.  Immune responses to influenza immunization in children receiving maintenance chemotherapy for acute lymphoblastic leukemia , 2004, Pediatric blood & cancer.

[33]  Yu-Chia Hsieh,et al.  Response to influenza vaccine in children with leukemia undergoing chemotherapy. , 2002, Journal of the Formosan Medical Association = Taiwan yi zhi.

[34]  S. Madhi,et al.  Lower respiratory tract infections associated with influenza A and B viruses in an area with a high prevalence of pediatric human immunodeficiency type 1 infection , 2002, The Pediatric infectious disease journal.

[35]  A. Charlett,et al.  Response to influenza immunisation during treatment for cancer , 2001, Archives of disease in childhood.

[36]  O. Weiland,et al.  Influenza A in immunocompromised patients. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  J. Margolick,et al.  The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. , 1989, JAMA.

[38]  C. Hall,et al.  INFLUENZA IN CHILDREN WITH CANCER , 1987, Pediatric Research.

[39]  Gould Al,et al.  Effect of cancer chemotherapy on the immune response to influenza virus vaccine: review of published studies. , 1985, Reviews of infectious diseases.

[40]  H. Stiver,et al.  Impaired serum antibody response to inactivated influenza A and B vaccine in cancer patients. , 1978, Canadian Medical Association journal.

[41]  C. Hall,et al.  Influenza immunization in immunosuppressed children. , 1978, The Journal of pediatrics.

[42]  R. Webster,et al.  Reactogenicity and immunogenicity of bivalent influenza A and monovalent influenza B virus vaccines in high-risk children. , 1977, The Journal of infectious diseases.

[43]  R. Webster,et al.  Influenza in children and young adults with cancer. 20 cases , 1977, Cancer.